The Effect of Early Administration of PCSK9 Inhibitor to Acute Ischemic Stroke Patients Associated With Atherosclerosis on the Stroke Prognosis and Lipid Profile
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.
Also called NCT06083961
- Study
- In this atlas
Overview
- Design
- Interventional study; non-randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 200 participants
- Sponsor
- Sun U. Kwon
- Registry
-
NCT06083961
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- South Korea
- Registry status
- Unknown status
Technical summary
Registry record NCT06083961. Non-randomized; no masking; primary purpose treatment. Start 2023-10-15 (anticipated); primary completion 2026-10-15 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- The Effect of Early Administration of PCSK9 Inhibitor to Acute Ischemic Stroke Patients Associated With Atherosclerosis on the Stroke Prognosis and Lipid Profile
- Condition
- Stroke, Acute Ischemic
- Condition
- PCSK9 Inhibitor
- Intervention (Drug)
- Alirocumab
- Lead sponsor
- Sun U. Kwon
Record details
- Record id
cardio:ct-nct06083961- Content hash
81044cff7fba0429d6c6c6abb72553cb51317e70c1fe25f831ee5eaa06f0312d